About this trial
The literature on antipsychotic deprescribing highlights the difficulty in establishing a clear consensus on the most optimal strategy due to the diversity of clinical situations encountered in daily practice: who should be deprescribed, when, at what rate, what strategy to employ in case of relapse, etc.
The fear of relapse leads psychiatrists (particularly in France) to tend to maintain long-term treatment, even if the arguments for this maintenance may be debatable due to an uncertain benefit-risk balance. Conversely, patients often request a reduction or discontinuation, notably because of the side effects of the treatments.
This argument serves to justify the value of presenting unique clinical situations like those in this study in a publication. The goal is for readers to gain a practical understanding of the successes and difficulties of deprescribing in real-life situations.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults (≥18 years)
Patients with a psychotic or related disorder
Patients on long-term antipsychotic treatment, clinically stable, who accept or request a deprescription between January 1, 2021, and October 30, 2025
Disqualifiers
None
Trial population
Adults patients with a psychotic or related disorder
Trial design
Case-only
Retrospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Describe clinical situations where discontinuation of antipsychotics or a reduction of antipsychotics below the theoretically minimum recommended doses was possible.
Stopping or reducing treatment: * Some patients may do well with less medication, * or even without medication, under carefully monitored conditions.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.